MADISON, WISCONSIN, Jul. 28, 2016 — Exact Sciences Corporation announced the upsizing and pricing of its previously announced underwritten public offering of common stock. The company expects to raise a net proceeds of approximately $125.5 million from the offering, after deducting the underwriting discount and estimated offering expenses. The Company is selling 8,500,000 shares of common stock through the underwriters at a public offering price of $15.50 per share.
XMS Capital Partners served as financial advisor to Exact Sciences in connection with the offering. XMS has advised Exact Sciences on each of its equity offerings since 2009 as the company has funded the development and commercialization of Cologuard, the first and only FDA approved stool DNA noninvasive colorectal cancer screening test.